Several studies have investigated combined RT, PD-1/PD-L1, and CTLA-4 blockade while others have evaluated RT and immune checkpoint therapy with various combinations of chemotherapy, vaccine therapies, or targeted therapies across a spectrum of cancers [150–157]. The gene discussed is CTLA4; the disease is cancer.